Considering the multiple roles of Ang II and ET-1 in podocyte pathophysiology and the development of glomerulosclerosis, as previously discussed, dual ETAR and AT1R inhibition seems to be a logical approach for treatment of most forms of FSGS. The gene discussed is EDN1; the disease is glomerulosclerosis.